Cancer Centre of Southeastern Ontario, Kingston, Canada.
Breast Cancer Res Treat. 2011 Aug;129(1):265-8. doi: 10.1007/s10549-011-1542-y. Epub 2011 May 4.
To report an unanticipated pregnancy during ovarian ablation treatment with goserelin (10.8 mg SC every 12 weeks) in a 26-year old female with breast cancer. Review of the current literature and reports in MEDLINE, PubMED, and EMBASE using searches with keywords "goserelin, pregnancy, breast cancer, breast neoplasms, fertility, ovarian ablation, gonadotropin releasing hormone agonists/analogs, leuprolide, pregnancy complications, teratogens" (July-September 2010). Only 3 other reports of failures with goserelin administration at ablative doses in breast cancer patients were discovered. For physicians and breast cancer patients using a GnRH analog, it is important to be aware of the possibility of inadequate ovarian function suppression and the potential for pregnancy.
报告一例乳腺癌女性患者在接受戈舍瑞林（10.8mg，每 12 周皮下注射）卵巢去势治疗期间发生意外妊娠。检索 MEDLINE、PubMED 和 EMBASE 中的当前文献和报告，使用的关键词为“goserelin，pregnancy，breast cancer，breast neoplasms，fertility，ovarian ablation，gonadotropin releasing hormone agonists/analogs，leuprolide，pregnancy complications，teratogens”（2010 年 7-9 月）。仅发现另外 3 例乳腺癌患者使用戈舍瑞林进行去势剂量治疗失败的报告。对于使用 GnRH 类似物的医生和乳腺癌患者，必须意识到卵巢功能抑制不足的可能性和妊娠的潜在风险。
